Overview
Dynacure, a biotechnology company focused on improving the lives of patients with rare and orphan disorders, today announced that it has successfully raised a record €50 million in its third-round financing led by Perceptive Advisors. New investors participating in the financing include Bpifrance Large Venture and funds managed by Tekla Capital Management LLC. Dynacure’s existing investors Andera Partners, Bpifrance – through its FABS (Fonds Accélération Biotech Santé) and Fonds Biothérapies Innovantes et Maladies Rares funds -, Kurma Partners and Pontifax also meaningfully participated to the transaction.
Dynacure thus plans to continue the development of clinical trials of its flagship drug, DYN101, designed to combat centronuclear myopathies.
In this transaction, McDermott Will & Emery acted on corporate aspects for Dynacure with a team composed of partner Emmanuelle Trombe, and associates Mathilde Peschard, Shurong Qu and Lucie Martin.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With more than 20 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective—and often unexpected—solutions that propel success. More than 1,100 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
